Literature DB >> 8641324

In vitro inhibition of midazolam and quinidine metabolism by flavonoids.

H R Ha1, J Chen, P M Leuenberger, A U Freiburghaus, F Follath.   

Abstract

Studies in humans in vivo have demonstrated that substances found in grapefruit juice may increase the bioavailability of dihydropyridine derivatives as a result of the inhibition of liver enzyme activities by flavonoids found in grapefruit. Since the metabolism of dihydropyridine drugs is mediated by cytochrome P-450 (CYP) 3A4, it has been hypothesized that flavonoids may also influence the metabolism of other drugs, such as midazolam and quinidine, which are biotransformed by the same CYP isoform. Three flavonoids, kaempferol, naringenin and quercetin, are found in grapefruit juice but not in orange juice. The effect of these substances on the metabolism of midazolam and quinidine has been investigated in human liver microsomes. In the concentration range 10-160 microM the inhibitory potential of flavonoids was the same for both of the tested drugs; it decreased in the order quercetin >> kaempferol > naringenin. The data suggest that the flavonoids found in grapefruit juice may influence the kinetics of midazolam and quinidine in man.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8641324     DOI: 10.1007/bf00194952

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  32 in total

1.  Interaction of citrus juices with felodipine and nifedipine.

Authors:  D G Bailey; J D Spence; C Munoz; J M Arnold
Journal:  Lancet       Date:  1991-02-02       Impact factor: 79.321

2.  In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids.

Authors:  F P Guengerich; D H Kim
Journal:  Carcinogenesis       Date:  1990-12       Impact factor: 4.944

3.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

Authors:  T Kronbach; D Mathys; M Umeno; F J Gonzalez; U A Meyer
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

Review 4.  The flavonoids. A class of semi-essential food components: their role in human nutrition.

Authors:  J Kühnau
Journal:  World Rev Nutr Diet       Date:  1976       Impact factor: 0.575

5.  Inhibition of ethoxy- and pentoxy-resorufin dealkylases of rat liver by flavones and flavonols: structure-activity relationship.

Authors:  M H Siess; A Pennec; E Gaydou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jul-Sep       Impact factor: 2.441

6.  Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons.

Authors:  T Shimada; M V Martin; D Pruess-Schwartz; L J Marnett; F P Guengerich
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

7.  Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem.

Authors:  L Pichard; G Gillet; I Fabre; I Dalet-Beluche; C Bonfils; J P Thenot; P Maurel
Journal:  Drug Metab Dispos       Date:  1990 Sep-Oct       Impact factor: 3.922

8.  In vitro forecasting of drugs which may interfere with the biotransformation of midazolam.

Authors:  M P Gascon; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.

Authors:  D G Bailey; J M Arnold; C Munoz; J D Spence
Journal:  Clin Pharmacol Ther       Date:  1993-06       Impact factor: 6.875

10.  Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram.

Authors:  R E Benton; P K Honig; K Zamani; L R Cantilena; R L Woosley
Journal:  Clin Pharmacol Ther       Date:  1996-04       Impact factor: 6.875

View more
  10 in total

1.  Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.

Authors:  Yoko Honda; Fumihiko Ushigome; Noriko Koyabu; Satoshi Morimoto; Yukihiro Shoyama; Takeshi Uchiumi; Michihiko Kuwano; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

2.  Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity.

Authors:  Gareth E Lim; Timao Li; Harpal S Buttar
Journal:  Exp Clin Cardiol       Date:  2003

Review 3.  Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance.

Authors:  U Fuhr
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

4.  Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4.

Authors:  A Ohnishi; H Matsuo; S Yamada; H Takanaga; S Morimoto; Y Shoyama; H Ohtani; Y Sawada
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

5.  Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.

Authors:  C C Libersa; S A Brique; K B Motte; J F Caron; L M Guédon-Moreau; L Humbert; A Vincent; P Devos; M A Lhermitte
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

Review 6.  Drug interactions with grapefruit juice.

Authors:  B Ameer; R A Weintraub
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

Review 7.  Applications of Friedel-Crafts reactions in total synthesis of natural products.

Authors:  Majid M Heravi; Vahideh Zadsirjan; Pegah Saedi; Tayebeh Momeni
Journal:  RSC Adv       Date:  2018-12-03       Impact factor: 4.036

Review 8.  Medicinal importance of grapefruit juice and its interaction with various drugs.

Authors:  Jawad Kiani; Sardar Z Imam
Journal:  Nutr J       Date:  2007-10-30       Impact factor: 3.271

9.  Interaction between grapefruit juice and diazepam in humans.

Authors:  M Ozdemir; Y Aktan; B S Boydag; M I Cingi; A Musmul
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.569

Review 10.  Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.

Authors:  Mohamed Elmeliegy; Manoli Vourvahis; Cen Guo; Diane D Wang
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.